<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266420</url>
  </required_header>
  <id_info>
    <org_study_id>14 SEIN 09</org_study_id>
    <nct_id>NCT02266420</nct_id>
  </id_info>
  <brief_title>Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size &lt; or = 10 mm (pT1a/b) Versus pT1c T2 &lt; or = 30 mm</brief_title>
  <acronym>COCABIO000</acronym>
  <official_title>Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size &lt; or = 10 mm (pT1a/b) Versus pT1c T2 &lt; or = 30 mm.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized and multicenter study designed to compare biological&#xD;
      features between pN0 triple negative breast cancer (TNBC) with size ≤ 10 mm (pT1a/b) versus&#xD;
      pT1c T2 ≤ 30 mm.&#xD;
&#xD;
      All consecutive patients will be recruited by each investigator after completion of surgery.&#xD;
      No modification of standard management according to each investigator center will be done.&#xD;
      All patients will then be followed each year during 5 years in order to collect the following&#xD;
      events: local and loco regional recurrence, metastatasis, second cancer, death or not and the&#xD;
      cause.&#xD;
&#xD;
      At initial visit, a 10 mL blood sample will be collected (= study intervention) and&#xD;
      immediately processed for serum storage; all serum samples will be stored at -80°C and may be&#xD;
      used for the purpose of further scientific research.&#xD;
&#xD;
      A representative formalin-fixed paraffin-embedded tumor block of all 200 samples will be&#xD;
      addressed at the Institut Claudius Regaud for central collection which will consist of one&#xD;
      haematoxylin-eosin stained slide for central histological review, up to 15 unstained slides&#xD;
      for DNA extraction (after microdissection), and construction of a tissue micro-array (TMA).&#xD;
&#xD;
      Extracted DNA from 100 samples (50 in each group) will then be transferred to Institut Paoli&#xD;
      Calmettes, Marseille; extracted DNA will be subjected to array-CGH analysis in order to&#xD;
      detect gene copy number alterations such as gains/amplifications/deletions, and to next&#xD;
      generation sequencing (NGS; MiSeq, Illumina) using a panel of ~400 genes for mutation&#xD;
      detection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2014</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker signature for pT1a/b pN0 triple-negative breast cancers versus pN0 triple-negative breast cancers with size &gt; or = 11 mm and &lt; or = 30 mm.</measure>
    <time_frame>3 years.</time_frame>
    <description>biomarker signature will be defined from the protein expression of one or several biomarker(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival.</measure>
    <time_frame>7 years.</time_frame>
    <description>Disease Free Survival is defined as the time from inclusion until any recurrence (local or regional), contro-lateral breast cancer, second primary breast cancer, distant metastasis, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival.</measure>
    <time_frame>7 years.</time_frame>
    <description>Metastasis Free Survival is defined as the time from inclusion until distant metastasis or last follow-up news (censored data). All other events are ignored for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>7 years.</time_frame>
    <description>Overall survival is defined as the time from inclusion until death from any cause or last follow-up news (censured data).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description and comparison of gene copy number (array-CGH) and gene mutation (targeted NGS) between pT1a/b pN0 triple-negative breast cancer versus pN0 triple-negative breast cancer with size ≥ 11 mm and ≤ 30 mm.</measure>
    <time_frame>7 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Triple Negative Breast Cancers Without Lymph-node Involvement and &lt; or = 30 mm</condition>
  <arm_group>
    <arm_group_label>TNBC pT1a/b with size &lt; or = 10 mm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with pN0 triple negative breast tumor with size &lt; or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNBC pT1c T2 with size &lt;or = 30 mm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with pN0 triple negative breast tumor with size &lt; or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood samples of 10 mL</intervention_name>
    <description>Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.</description>
    <arm_group_label>TNBC pT1a/b with size &lt; or = 10 mm</arm_group_label>
    <arm_group_label>TNBC pT1c T2 with size &lt;or = 30 mm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman with age ≥ 18 years.&#xD;
&#xD;
          2. Patient who completed surgery for his breast cancer and for which definitive&#xD;
             histo-pathological analysis of surgical specimen is available.&#xD;
&#xD;
          3. Invasive breast carcinoma pN0 or pN(i+) with histological tumor size ≤ 10 mm (pT1a/b&#xD;
             subgroup) or invasive breast carcinoma with histological tumor size &gt; 10 mm and ≤ 30&#xD;
             mm (pT1c T2 ≤ 30 mm control group).&#xD;
&#xD;
          4. Patient with HER2-negative breast carcinoma: immuno-histochemistry (IHC) score = 0, 1+&#xD;
             or 2+ and in situ hybridization (FISH, CISH, or SISH) negative (local laboratory&#xD;
             testing).&#xD;
&#xD;
          5. Patient with ER and PR negative invasive carcinoma (&lt; 1% stained cells by&#xD;
             immuno-histochemistry assay) (local laboratory testing).&#xD;
&#xD;
          6. In case of multifocality, the histological size of the largest tumor must be ≤ 10 mm&#xD;
             or ≤ 30 mm according to the inclusion subgroup. All lesions must be ER, PR and&#xD;
             HER2-negative.&#xD;
&#xD;
          7. In case of breast conserving surgery, clear margins are required.&#xD;
&#xD;
          8. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
          9. Patient information and written informed consent form signed prior to any study&#xD;
             specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any previous malignancy of the breast or other site, with the exception&#xD;
             of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer&#xD;
             totally resected.&#xD;
&#xD;
          2. Non-invasive breast carcinoma (i.e. ductal carcinoma in situ exclusively).&#xD;
&#xD;
          3. Inoperable breast invasive carcinoma.&#xD;
&#xD;
          4. Synchronous bilateral breast cancer.&#xD;
&#xD;
          5. Patients who received neo-adjuvant treatment (radiotherapy or chemotherapy or other&#xD;
             before surgery).&#xD;
&#xD;
          6. Pregnant or breast-feeding women.&#xD;
&#xD;
          7. Any psychological, familial, geographic or social situation, according to the judgment&#xD;
             of investigator, potentially preventing the provision of informed consent or&#xD;
             compliance to study procedure.&#xD;
&#xD;
          8. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence DALENC, Md.</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest - Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Emile ROUX</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <zip>43000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES - HOPITAL DUPUYTREN</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique La Croix Du Sud</name>
      <address>
        <city>Quint-Fonsegrives</city>
        <zip>31130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest - Site Rene Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>immuno-histochemistery</keyword>
  <keyword>genomic profiles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

